FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 56 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $929,000 | -51.7% | 305,500 | -62.2% | 0.35% | -51.7% |
Q2 2019 | $1,923,000 | -36.5% | 808,000 | 0.0% | 0.72% | -44.7% |
Q1 2019 | $3,030,000 | +4.4% | 808,000 | 0.0% | 1.31% | -9.4% |
Q4 2018 | $2,901,000 | -37.3% | 808,000 | 0.0% | 1.44% | -24.1% |
Q3 2018 | $4,630,000 | +173.5% | 808,000 | +139.1% | 1.90% | +139.7% |
Q2 2018 | $1,693,000 | -1.6% | 338,000 | +0.7% | 0.79% | -5.3% |
Q1 2018 | $1,721,000 | -18.8% | 335,500 | -4.9% | 0.84% | -26.7% |
Q4 2017 | $2,120,000 | +47.6% | 352,741 | +36.4% | 1.14% | +28.0% |
Q3 2017 | $1,436,000 | -13.0% | 258,667 | -27.3% | 0.89% | -24.2% |
Q2 2017 | $1,650,000 | +2.4% | 355,667 | +9.2% | 1.18% | -13.6% |
Q1 2017 | $1,612,000 | -45.8% | 325,667 | +21.5% | 1.36% | -47.9% |
Q4 2016 | $2,976,000 | +15.6% | 268,067 | -3.6% | 2.62% | +45.8% |
Q3 2016 | $2,575,000 | +110.5% | 278,067 | +44.4% | 1.79% | +85.0% |
Q2 2016 | $1,223,000 | +58.0% | 192,567 | +62.3% | 0.97% | +45.1% |
Q1 2016 | $774,000 | +57.0% | 118,671 | +95.3% | 0.67% | +52.2% |
Q4 2015 | $493,000 | – | 60,770 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |